New publication last week on Elsevier about:

“Evolution of FMT – From early clinical to standardized treatments”

Authors: Stephanie L Servetas ¹, Phillip J Daschner ², Cyril Guyard ³, Vincent Thomas ⁴, Herve Affagard ⁵, Chrysi Sergaki ⁶, Harry Sokol ⁷, Jennifer A Wargo ⁸, Gary D Wu ⁹, Philippe Sabot ¹⁰

• DOI: 10.1016/j.biologicals.2022.01.004

Affiliations

• ¹Complex Microbial Systems Group, Biosystems and Biomaterials Divison, National Institute of Standards and Technology, Gaithersburg, MD, USA. Electronic address: stephanie.servetas@nist.gov.
• ²Division of Cancer Biology, National Cancer Institute, Bethesda, MD, USA. Electronic address: daschnep@mail.nih.gov.
• ³BIOASTER Technological Research Institute, Lyon, France. Electronic address: Cyril.GUYARD@bioaster.org.
• ⁴BIOASTER Technological Research Institute, Lyon, France. Electronic address: Vincent.THOMAS@bioaster.org.
• ⁵MaaT Pharma, 70 Avenue Tony Garnier, 69007, Lyon, France. Electronic address: haffagard@maat-pharma.com.
• ⁶Microbiome Section, National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, EN6 3QG, United Kingdom. Electronic address: Chrysi.Sergaki@nibsc.org.
• ⁷Assistance Publique des Hôpitaux de Paris, Saint-Antoine Hospital, Gastroenterology Department, 184 rue du faubourg Saint-Antoine 75571 Paris cedex 12, France. Electronic address: harry.sokol@aphp.fr.
• ⁸Departments of Surgical Oncology and Genomic Medicine, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: JWargo@mdanderson.org.
• ⁹Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: gdwu@pennmedicine.upenn.edu.
• ¹⁰International Alliance for Biological Standardization, IABS, Geneva, Switzerland. Electronic address: philippe.sabot@iabs.org.